Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 15, Issue 7, Pages 1085-1091Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1517/14712598.2015.1055241
Keywords
diffuse large B-cell lymphoma; follicular lymphoma; ofatumumab
Ask authors/readers for more resources
Introduction: Ofatumumab is a second-generation humanized monoclonal antibody targeting CD20 registered for the treatment of patients with relapsing/refractory chronic lymphocytic leukemia. This review will describe the activity of ofatumumab in patients with CD20 B-cell lymphomas. Areas covered: A review of all manuscript published on ofatumumab activity in B-cell lymphomas is presented with conclusions on the future use of this antibody in these patients. Expert opinion: Ofatumumab activity is low in indolent or aggressive B-cell lymphomas. The future of this drug is challenged by new monoclonal antibodies and new targeted drugs.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available